Objective: The study aimed to estimate the incidence, prevalence and disability-adjusted life years (DALY) for traumatic brain injury (TBI) in New Zealand (NZ) in 2010. Methods: A multi-state life table model was constructed using inputs from the Brain Injury Outcomes New Zealand in the Community study for the first-ever incidence of TBI in a lifetime and its severity distribution, from the NZ Ministry of Health's Mortality Collection for the data on TBI mortality and from Statistics of NZ for the population data. The modeled estimate of prevalence was combined with the disability weights for TBI (by stage and severity level) from the Global Burden of Disease 2010 study to obtain estimates of health loss (DALYs) for TBI. Results: Approximately, 11,300 first-ever incident TBIs occurred in NZ during 2010, with 527,000 New Zealanders estimated to have ever experienced a TBI (prevalent cases). The estimated 20,300 DALYs attributable to TBI accounted for 27% of total injury-related health loss and 2.4% of DALYs from all causes. Of the total DALYs attributable to TBI, 71% resulted from fatal injuries. However, non-fatal outcomes accounted for a substantial share of the burden (29%) with mild TBI making the greater contribution of non-fatal outcomes (56%). Conclusions: The burden of TBI in NZ is substantial, and mild TBI contributes to a major part of non-fatal outcomes.

Keywords:
Traumatic brain injury, Incidence, Prevalence, Disability-adjusted life years and DISMOD
1.
Feigin VL, Theadom A, Barker-Collo S, Starkey NJ, McPherson K, Kahan M, et al: Incidence of traumatic brain injury in New Zealand: a population-based study. Lancet Neurol 2013;12:53-64.
2.
Te Ao B, Brown P, Tobias M, Ameratunga S, Barker-Collo S, Theadom A, et al: Cost of traumatic brain injury in New Zealand: evidence from a population-based study. Neurology 2014;83:1645-1652.
3.
Corrigan JD, Selassie AW, Orman JA: The epidemiology of traumatic brain injury. J Head Trauma Rehabil 2010;2:72-80.
4.
Ribbers GM: Traumatic brain injury rehabilitation in the Netherlands: dilemmas and challenges. J Head Trauma Rehabil 2007;22:234-238.
5.
McGarry LJ, Thompson D, Millham FH, Cowell L, Snyder PJ, Lenderking WR, et al: Outcomes and costs of acute treatment of traumatic brain injury. J Trauma 2002;53:1152-1159.
6.
McGregor K, Pentland B: Head injury rehabilitation in the U.K.: an economic perspective. Soc Sci Med 1997;45:295-303.
7.
Leibson CL, Brown AW, Hall Long K, Ransom JE, Mandrekar J, Osler TM, et al: Medical care costs associated with traumatic brain injury over the full spectrum of disease: a controlled population-based study. J Neurotrauma 2012;29:2038-2049.
8.
Cassidy JD, Carroll LJ, Peloso PM, Borg J, von Holst H, Holm L, et al; WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury: Incidence, risk factors and prevention of mild traumatic brain injury: results of the who collaborating centre task force on mild traumatic brain injury. J Rehabil Med 2004;43(suppl):28-60.
9.
Tate RL, McDonald S, Lulham JM: Incidence of hospital-treated traumatic brain injury in an Australian community. Aust N Z J Public Health 1998;22:419-423.
10.
Murray C, Vos T, Lozano R, et al: Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet 2012;380:2197-2223.
11.
Carroll LJ, Cassidy JD, Holm L, et al: Methodological issues and research recommendations for mild traumatic brain injury: the who collaborating centre task force on mild traumatic brain injury. J Rehabil Med 2004;43(suppl):113-125.
12.
Theadom A, Barker-Collo S, Feigin VL, Starkey NJ, Jones K, Jones A, et al: The spectrum captured: a methodological approach to studying incidence and outcomes of traumatic brain injury on a population level. Neuroepidemiology 2012;38:18-29.
13.
Barker-Collo SL, Feigin VL: Capturing the spectrum: suggested standards for conducting population-based traumatic brain injury incidence studies. Neuroepidemiology 2009;32:1-3.
14.
Barendregt JJ, Van Oortmarssen GJ, Vos T, Murray CJ: A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. Popul Health Metr 2003;1:4.
15.
Barendregt JJ, Ott A: Consistency of epidemiologic estimates. Eur J Epidemiol 2005;20:827-832.
16.
Roberts MG, Tobias MI: The use of multistate life-table models for improving population health. IMA J Math Appl Med Biol 2001;18:119-130.
17.
World Health Organization, Che G (ed): Age Standardization of Rates: A New WHO Standard. WHO, 2000.
18.
Salomon JA, Vos T, Hogan DR, et al: Common values in assessing health outcomes from disease and injury: disability weights measurement study for the global burden of disease study 2010. Lancet 2012;380:2129-2143.
19.
Murray CJ, Ezzati M, Flaxman AD, et al: GBD 2010: design, definitions, and metrics. Lancet 2012;380:2063-2066.
20.
Jennett B, Bond M: Assessment of outcome after severe brain damage. Lancet 1975;1:480-484.
21.
Ministry of Health (New Zealand) Ways and Means: A Report on Methodology from the New Zealand Burden of Diseases, Injuries and Risk Factors Study, 2006-2016. Wellington, Ministry of Health, 2012.
22.
Ministry of Health and Accident Compensation Corporation. Injury-related Health Loss: A Report from the New Zealand Burden of Diseases, Injuries and Risk Factors Study, 2006-2016. Wellington, Ministry of Health, 2013.
23.
Tagliaferri F, Compagnone C, Korsic M, Servadei F, Kraus J: A systematic review of brain injury epidemiology in Europe. Acta Neurochir (Wien) 2006;148:255-268.
24.
McKinlay A, Grace RC, Horwood LJ, Fergusson DM, Ridder EM, MacFarlane MR: Prevalence of traumatic brain injury among children, adolescents and young adults: prospective evidence from a birth cohort. Brain Inj 2008;22:175-181.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.